Table 2 Comorbidities among Covid-19 patients admitted for treatment. The number and percentage of patients for each variable are provided in columns “survivor” and “non-survivor”. The P values is are based on comparisons between “survivor” and “non-survivor” patients. CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease
From: Higher comorbidities and early death in hospitalized African-American patients with Covid-19
Comorbidities | All Patients no./total (%) | Survivors no. (%) | Non-survivors no. (%) | Odds Ratio (95% CI) | P value |
|---|---|---|---|---|---|
Asthma | 30/475 (6) | 9 (30) | 21 (70) | 2.77 (1.18–7.04) | 0.01 |
Autoimmune disease | 37/495 (7) | 22 (59) | 15 (41) | 0.71 (0.33–1.47) | 0.39 |
History of cancer | 43/496 (9) | 14 (33) | 29 (67) | 2.39 (1.18–5.03) | 0.010 |
COPD | 36/481 (7) | 16 (44) | 20 (56) | 1.48 (0.71–3.16) | 0.297 |
Coronary Artery Disease | 42/529 (8) | 10 (24) | 32 (76) | 3.77 (1.76–8.81) | < 0.001 |
Congestive Heart Failure | 25/529 (5) | 16 (64) | 9 (36) | 0.59 (0.22–1.45) | 0.22 |
CKD without dialysis | 73/504 (14) | 28 (38) | 45 (62) | 1.88 (1.11–3.27) | 0.016 |
CKD with dialysis | 11/504 (2) | 9 (81) | 2 (18) | 0.23 (0.02–1.14) | 0.06 |
ESRD on dialysis | 50/504 (10) | 34 (68) | 16 (32) | 0.47 (0.23–0.90) | 0.02 |
Diabetes mellitus | 289/517 (56) | 139 (48) | 150 (52) | 1.48 (1.03–2.13) | 0.03 |
Hyperlipidemia | 82/529 (16) | 34 (42) | 48 (58) | 1.63 (0.98–2.72) | 0.05 |
Hypertension | 416/517 (79) | 212 (51) | 204 (49) | 1.35 (0.85–2.15) | 0.184 |
Immune suppression | 25/489 (5) | 17 (68) | 8 (32) | 0.48 (0.17–1.21) | 0.102 |
All patients ≥ 1 Comorbidities | 517/529 (98) | 271 (99) | 246 (96) | – | – |